IP Library › Granted Patent US 7,528,282

Granted Patent B2

US 7,528,282 · App. 11/733,636 · Granted May 5, 2009

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Assignee: Abbott Laboratories

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,528,282
App. No.: 11/733,636
Granted: May 5, 2009
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

Claims (180)

1. A compound of formula (I),

wherein

one of A 1 , A 2 , A 3 and A 4 is —CO 2 R 17 and —C(O)—N(R 18 R 19 ) and the remaining members of the group consisting of A 1 , A 2 , A 3 and A 4 are each individually selected from the group consisting of hydrogen, and alkyl;

D is a bond;

E is aryl;

R 1 is selected from the group consisting of hydrogen and alkyl;

R 2 is selected from the group consisting of hydrogen, alkyl and cycloalkyl;

R 3 and R 4 are each independently selected from the group consisting of hydrogen, alkyl, carboxyalkyl, carboxycycloalkyl, cycloalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle and heterocyclealkyl, or R 3 and R 4 together with the atom to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle;

R 17 is selected from the group consisting of hydrogen, alkyl, carboxyalkyl, cycloalkyl, carboxycycloalkyl, aryl, arylalkyl, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heterocycle, heterocyclealkyl and heterocycleoxyalkyl;

R 18 and R 19 are each independently selected from the group consisting of hydrogen, alkoxy, alkyl, alkylsufonyl, carboxy, carboxyalkyl, carboxycycloalkyl, cycloalkyl, cycloalkyloxy, cycloalkylsulfonyl, aryl, arylalkyl, aryloxy, aryloxyalkyl, alylsulfonyl, heteroaryl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylsulfonyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, heterocycleoxy, heterocyclesulfonyl and hydroxy, or R 18 and R 19 together with the atom to which they are attached form a heterocycle;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

2. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen.

3. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 , R 2 , R 3 and R 4 are hydrogen.

4. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 , R 2 and R 3 are hydrogen; and

R 4 is alkyl.

5. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; and

R 3 and R 4 are alkyl.

6. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; and

R 3 and R 4 together with the atom to which they are attached form a ring selected from the group consisting of cycloalkyl and heterocycle.

7. The compound according to claim 1 , wherein

A 2 , A 3 , A 4 , R 1 and R 2 are hydrogen; and

R 3 and R 4 together with the atom to which they are attached form a cycloalkyl ring.

8. The compound according to claim 1 selected from the group consisting of

E-4-{[2-methyl-2-(4-pyridin-4-ylphenyl)propanoyl]amino}adamantane-1-carboxamide;

E-4-[(2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}propanoyl)amino]adamantine-1-carboxamide;

E-4-({2-methyl-2-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]propanoyl}amino) adamantane-1-carboxamide;

E-4-({2-[4-(3,5-dimethylisoxazol-4-yl)phenyl]-2-methylpropanoyl}amino) adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-pyridin-3-ylphenyl)propanoyl]amino}adamantane-1-carboxamide;

E-4-({2-methyl-2-[4-(1H-pyrazol-4-yl)phenyl]propanoyl }amino)adamantane-1-carboxamide;

3-{[({(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamantyl}carbonyl)amino]methyl}benzoic acid;

E-4-(2-methyl-2-phenyl-propionylamino)-adamantane-1-carboxylic acid;

E-4-(2-methyl-2-phenyl-propionylamino)-adamantane-1-carboxylic acid amide;

E-4-{[2-(4-chlorophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(4-bromophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(3-bromophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(4-hydroxyphenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-phenoxyphenyl)propanoyl]amino}adamantane-1-carboxamide;

methyl (E)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxylate;

(E)-N-[3-(aminocarbonyl)benzyl]-4-[(2-methyl-2-phenylpropanoyl)amino]adamantine-1-carboxamide;

(E)-4-{[2-methyl-2-(4-phenoxyphenyl)propanoyl]amino}adamantane-1-carboxylic acid;

(E)-N-[4-(aminosulfonyl)benzyl]-4-[(2-methyl-2-phenylpropanoyl)amino]-adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[4-(pentyloxy)phenyl]propanoyl}amino) adamantane-1-carboxylic acid;

(E)-4-({2-[4-(benzyloxy)phenyl]-2-methylpropanoyl}amino)adamantane-1-carboxylic acid;

(E)-4-{[2-(4-chlorophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxylic acid;

4-{[({(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamantyl}carbonyl) amino]methyl}benzoic acid;

E-4-{[1-(4-chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid;

E-4-[(1-phenyl-cyclopropanecarbonyl)-amino]-adamantane-1-carboxylic acid;

E-4-{[1-(4-chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid amide;

E-4-[(1-phenyl-cyclopropanecarbonyl)-amino]-adamantane-1-carboxylic acid amide;

E-4-({[1-(4-chlorophenyl)cyclohexyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-chlorophenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-chlorophenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-{[(1-phenylcyclopentyl)carbonyl]amino}adamantane-1-carboxamide;

E-4-({[1-(3-fluorophenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(2-chloro-4-fluorophenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-fluorophenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(2-fluorophenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(2,4-dichlorophenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-methoxyphenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-methylphenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxamide;

E-4-({[1-(4-methoxyphenyl)cyclopentyl]carbonyl}amino)adamantane-1-carboxamide;

methyl (E)-4-{[(1-phenylcyclopropyl)carbonyl]amino}adamantane-1-carboxylate;

methyl (E)-4-({[1-(4-chlorophenyl)cyclobutyl]carbonyl}amino)adamantane-1-carboxylate;

(E)-4-({[1-(4-methylphenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxylic acid;

(E)-4-({[1-(2,4-dichlorophenyl)cyclopropyl]carbonyl}amino)adamantane-1-carboxylic acid;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

9. The compound according to claim 1 selected from the group consisting of

methyl (E)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxylate;

(E)-4-({2-methyl-2-[3-(1,3-thiazol-4-ylmethoxy)phenyl]propanoyl}amino) adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[3-(morpholin-4-ylmethyl)phenyl]propanoyl}amino) adamantane-1-carboxamide;

(E)-4-[(2-{3-[2-(1H-imidazol-1-yl)ethoxy]phenyl }-2-methylpropanoyl)amino]-adamantane-1-carboxamide;

(E)-N-[3-(aminocarbonyl)benzyl]-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxamide;

methyl (E)-4-({[1-(4-chlorophenyl)cyclobutyl]carbonyl}amino)adamantane-1-carboxylate;

(E)-4-[(2-methyl-2-(4-[(E)-2-pyridin-4-ylvinyl]phenyl)propanoyl)amino]adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[3-(2-morpholin-4-ylethoxy)phenyl]propanoyl}amino) adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[4-(1,3-thiazol-4-ylmethoxy)phenyl]propanoyl}amino) adamantane-1-carboxylic acid;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(1,3-thiazol-5-ylmethyl) adamantane-1-carboxamide;

4-{[({(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamantyl}carbonyl)amino]methyl}benzoic acid;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-4-ylmethyl) adamantane-1-carboxamide;

(E)-N-(2-furylmethyl)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxamide;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-3-ylmethyl)adamantane -1-carboxamide;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-2-ylmethyl)adamantane -1-carboxamide; and

(E)-4-[(2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}propanoyl)amino]adamantane-1-carboxylic acid;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I) of claim 1 in combination with a pharmaceutically suitable carrier.

11. The compound according to claim 1 selected from the group consisting of

E-4-(2-methyl-2-phenyl-propionylamino)-adamantane-1-carboxylic acid;

methyl (E)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxylate;

E-4-({2-methyl-2-[4-(1H-pyrazol-4-yl)phenyl]propanoyl}amino)adamantane-1-carboxamide;

(E)-4-{[2-methyl-2-(4-phenoxyphenyl)propanoyl]amino}adamantane-1-carboxylic acid;

(E)-4-({2-methyl-2-[4-(pentyloxy)phenyl]propanoyl}amino)adamantane-1-carboxylic acid;

(E)-4-({2-[4(benzyloxy)phenyl]-2-methylpropanoyl}amino)adamantane-1-carboxylic acid;

(E)-4-{[2-(4-chlorophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxylic acid;

methyl (E)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxylate;

(E)-4-({2-methyl-2-[4-(1,3-thiazol-4-ylmethoxy)phenyl]propanoyl}amino) adamantane-1-carboxylic acid; and

(E)-4-[(2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}propanoyl)amino]adamantane-1-carboxylic acid;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

12. The compound according to claim 1 selected from the group consisting of

E-4-(2-methyl-2-phenyl-propionylamino)-adamantane-1-carboxylic acid amide;

E-4-{[2-(4-chlorophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(4-bromophenyl )-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(3-bromophenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-(4-hydroxyphenyl)-2-methylpropanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-phenoxyphenyl)propanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-pyridin-4-ylphenyl)propanoyl]amino}adamantane-1-carboxamide;

E-4-[(2-methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}propanoyl)amino]adamantane-1-carboxamide;

E-4-({2-methyl-2-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]propanoyl}amino) adamantane-1-carboxamide;

E-4-({2-[4-(3,5-dimethylisoxazol-4-yl)phenyl]-2-methylpropanoyl}amino) adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-pyridin-3-ylphenyl)propanoyl]amino}adamantane-1-carboxamide;

E-4-{[2-methyl-2-(4-phenoxyphenyl )propanoyl]amino}adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[3-(1,3-thiazol-4-ylmethoxy)phenyl]propanoyl}amino) adamantane-1-carboxamide;

(E)-4-({2-methyl-2-[3-(morpholin-4-ylmethyl)phenyl]propanoyl}amino) adamantane-1-carboxamide;

(E)-4-[(2-{3-[2-(1H-imidazol-1-yl)ethoxy]phenyl}-2-methylpropanoyl)amino]-adamantane-1-carboxamide;

(E)-N-[3-(aminocarbonyl)benzyl]-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxamide;

(E)-4-[(2-methyl-2-(4-[(E)-2-pyridin-4-ylvinyl]phenyl)propanoyl)amino]adamantane-1-carboxamide; and

(E)-4-({2-methyl-2-[3-(2-morpholin-4-ylethoxy)phenyl]propanoyl}amino) adamantane-1-carboxamide;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

13. The compound according to claim 1 selected from the group consisting of

3-{[({(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamanty}carbonyl)amino]methyl}benzoic acid;

(E)-N-[3-(aminocarbonyl)benzyl]-4-[2-methyl-2-phenylpropanoy)amino]adamantane-1-carboxamide;

E)-N-[4-(aminosulfonyl)benzyl]-4-[(2-methyl-2-phenylpropanoyl)amino]-adamantane-1-carboxamide;

4-{[{(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamantyl}carbonyl) amino]methyl}benzoic acid;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(1,3-thiazol-5-ylmethyl) adamantane-1-carboxamide;

4-{({[(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-1-adamanty}carbonyl)amino]methyl}benzoic acid;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-4-ylmethyl) adamantane-1-carboxamide;

(E)-N-(2-furylmethyl)-4-[(2-methyl-2-phenylpropanoyl)amino]adamantane-1-carboxamide;

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-3-ylmethyl)adamantane-1-carboxamide; and

(E)-4-[(2-methyl-2-phenylpropanoyl)amino]-N-(pyridin-2-ylmethyl)adamantane-1-carboxamide;

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof.

14. The compound according to claim 1 selected from the group consisting of